ViewsML Raises $4.8M Seed With Plans To Replace Tissue Staining With AI.
ViewsML closed a $4.9M seed for AI virtual biomarker staining from standard pathology images.
Category AI In Biotech
Novo Nordisk Called OpenAI. So Did Everyone Else.
Novo Nordisk partners with OpenAI as AI drug discovery deal flow surpasses $5B in five months.
One Bought a Podcast. The Other Bought a Lab.
Anthropic dropped $400M on a 9-person biotech AI startup. The same day, OpenAI bought a podcast. That tells you everything.
$787 Million Says AI Can Design Better Biologics Than You
An AI-native biologics company just raised $787M with Sanofi and a Pfizer/Hillhouse fund backing it — and they already have a Phase 2 asset.
Teaching a Gene Editor to Optimize Itself
Specific Biologics just got government funding to build a machine learning layer on top of its Dualase gene editing platform — targeting repeat expansion diseases like ALS.
Molecular Glues Were Discovered by Accident. Not Anymore.
Molecular glues are biotech's hottest modality and its hardest to design rationally. Ternary thinks AI can change that.
220 Targets. Zero Antibodies. One AI Platform.
One-third of all FDA-approved drugs target GPCRs, but almost no antibodies do. Antiverse's AI platform is changing that — and the CF Foundation just signed on.